Targeting mutations in bladder cancer related to the ARID1A gene
Official title: Targeting ARID1A mutated Urothelial Carcinoma
Funded at VA Salt Lake City Healthcare System · NIH-10951535 · Data updated 2026-11-12
This study is looking at how changes in the ARID1A gene might affect bladder cancer in older Veterans, especially those who have been exposed to things like smoking, to help find better treatments for those with this gene mutation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Salt Lake City Healthcare System NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX005765-02 |
| Project ID | NIH-10951535 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are Veterans diagnosed with bladder cancer, particularly those with ARID1A mutations.
✕Less likely to help
Patients without bladder cancer or those whose tumors do not have ARID1A mutations may not benefit from this research.
What this research studies
This research investigates the role of the ARID1A gene mutation in bladder cancer, particularly in aging Veterans who are at higher risk due to factors like smoking and exposure to carcinogens. The study aims to understand how these mutations contribute to treatment resistance and cancer progression. By focusing on the epigenetic alterations associated with ARID1A, the research seeks to develop targeted therapies that could improve outcomes for patients with this specific mutation. The approach includes characterizing the biological mechanisms behind ARID1A mutations and their impact on cancer stem cell behavior.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for bladder cancer patients with ARID1A mutations, potentially improving treatment outcomes and reducing recurrence.
How similar studies have gone: While targeting specific genetic mutations in cancer is a growing field, this particular focus on ARID1A mutations in bladder cancer is relatively novel and has not been extensively tested in prior research.
Where this research is happening
-
VA Salt Lake City Healthcare System
Salt Lake City, United States Active
Researchers
- Principal investigator: Gupta, Sumati — VA Salt Lake City Healthcare System
- Study coordinator: Gupta, Sumati
Related research
Other NIH-funded projects on the same topics.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
Treating bladder cancer with ARID1A gene changes
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.